Swiss Biotech Stock News

UBS Group (SWX:UBSG) is back in focus after its Q4 2025 report showed net income of US$1.2b and full year profit of US$7.8b, along with progress on the Credit Suisse integration. See our latest analysis for UBS Group. The latest Q4 results, higher proposed dividend and the new share repurchase plan have arrived after a mixed run in the share price, with a 30 day share price return of 9.4% decline but a 90 day share price return of 11.53% and a 1 year total shareholder return of 14.88%,...

Most readers would already know that Burkhalter Holding's (VTX:BRKN) stock increased by 8.1% over the past three...

It's been a good week for Novartis AG ( VTX:NOVN ) shareholders, because the company has just released its latest...

Why Holcim’s new solar PPA in the Philippines matters for shareholders Holcim (SWX:HOLN) has signed a 20 year Power Purchase Agreement with Peak Energy to build a large behind the meter solar project for its cement plants in the Philippines, tying long term energy costs directly to renewable power. The 25 MegaWatt peak installation is expected to supply around 40 gigawatt hours of electricity a year to the Bacnotan and Norzagaray facilities, with Holcim buying the output while Peak Energy...

What ABB’s Recent Run Means For Its Valuation ABB’s share price story can look impressive at first glance, so if you are wondering whether the stock still offers value, it helps to separate the headlines from the actual numbers. Over the last week ABB’s return was 0.1%, over the last month it was 9.5%, year to date it was 8.5%, and over the last year it was 36.6%, with a 3 year return of 128.2% and a 5 year return of 204.3%. This raises fair questions about how much of the good news might...

Barry Callebaut (SWX:BARN) is back in focus after reporting a 22% drop in cocoa division sales volume for the quarter ending November 30, citing weak market demand and a tilt toward higher return cocoa segments. See our latest analysis for Barry Callebaut. The latest cocoa volume setback comes after a period of strong momentum in the share price, with a 12.69% 1 month share price return and an 18.16% 3 month share price return contributing to a 45.54% 1 year total shareholder return, even...

Most readers would already be aware that Swiss Prime Site's (VTX:SPSN) stock increased significantly by 15% over the...

Roche Holding reported highly positive topline Phase 2 results for its anti obesity drug candidate CT-388 and plans to start Phase 3 trials this quarter. The company also announced a collaboration between Roche Diagnostics and ChemoMetec to develop bioprocess monitoring solutions combining their technologies. Roche Holding (SWX:ROG) is drawing fresh attention after these updates, with its shares at CHF358.7 and a value score of 5. The stock has returned 3.4% over the past week and 8.7% over...

Givaudan SA recently reported its full-year 2025 results, with sales of CHF 7,472 million and net income of CHF 1,071 million, and announced an annual dividend of CHF 72.00 per share payable on March 25, 2026. Despite slightly lower net income and earnings per share than the previous year, the decision to raise the dividend highlights management’s willingness to return more cash to shareholders. We will now examine how Givaudan’s decision to increase its annual dividend despite softer...

As the eurozone economy continues its modest recovery, with improved consumer and business confidence, European markets have shown resilience amidst global trade and geopolitical concerns. In this environment, dividend stocks can offer stability and income potential, making them an attractive option for investors looking to navigate the current market dynamics.

Sensirion Holding AG has launched the SCD53, a highly intrinsically stable CO₂ sensor designed to maintain long-term accuracy without manual recalibration or exposure to outdoor air, while offering integrated humidity, temperature and optional pressure compensation in a compact, easily integrated package. By eliminating reliance on automatic baseline calibration and enhancing robustness against dust, vibrations and mechanical stress, the SCD53 directly targets challenging applications such...

Novartis (SWX:NOVN) is back in focus after releasing its fourth quarter and full year 2025 results, pairing high single digit sales growth and a proposed higher dividend with softer guidance for 2026 core operating income. See our latest analysis for Novartis. The recent earnings release, softer 2026 core income guidance and the proposed CHF3.70 dividend appear to be contributing to building momentum. The 30 day share price return of 9.4% and 1 year total shareholder return of 24.7% extend...

As the European markets navigate a landscape marked by earnings optimism amidst trade and geopolitical concerns, the pan-European STOXX Europe 600 Index has shown resilience with modest gains. Against this backdrop, identifying stocks that are trading below their estimated worth can offer potential opportunities for investors seeking value in an environment where confidence is strengthening and economic recovery continues at a steady pace.

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...

Why ARYZTA’s latest guidance is back in focus ARYZTA (SWX:ARYN) drew fresh attention after its 2025 sales and trading statement call on 22 January, alongside new earnings guidance for 2026 that points to revenue growth and improved performance for the year. For you as an investor, that combination of an updated outlook and a recent company communication creates a new reference point for reassessing ARYZTA’s current valuation, recent share price moves and the risks around its 2026 targets. See...

Idorsia has recently announced an exclusive license and supply agreement with EMS S.A. to register and commercialize its insomnia medicine QUVIVIQ (daridorexant) across Latin America, while also presenting long-term data on lucerastat suggesting disease-modifying potential in Fabry disease at the WORLDSymposium. Together, these developments highlight Idorsia’s push to expand QUVIVIQ into new geographies and progress lucerastat toward a defined regulatory path in a rare disease setting. We’ll...

In January 2026, BlackRock and Partners Group launched a first-of-its-kind multi-alternatives separately managed account on the Morgan Stanley wealth platform, giving advisors streamlined access to diversified private equity, private credit, and real assets through three outcome-aligned strategies. This structure is designed to remove common barriers to private market access by consolidating seven evergreen private market funds into a single, operationally simple solution for financial...

Cosmo Pharmaceuticals N.V. recently completed a private placement of 937,086 treasury shares, equivalent to about 5.3% of its outstanding shares, with Capital Group’s SMALLCAP World Fund, using only existing treasury stock and therefore avoiding dilution for current shareholders. The deal brings a globally recognized institutional investor into Cosmo’s shareholder base while providing additional financial flexibility to support its MedTech AI, dermatology, gastroenterology, and CDMO...

Sika recently expanded its global manufacturing network by opening five new plants in the United States, Argentina, Colombia, Bangladesh, and Tanzania to increase production capacity and reinforce its supply chain in key regions. This expansion underscores Sika’s emphasis on being closer to customers in growth markets, enhancing supply reliability and responsiveness across diverse construction material needs. We’ll now examine how this push to boost production capacity in key growth markets...

Adecco Group (SWX:ADEN) is back in focus after launching a global HR and talent consulting platform under its LHH brand. The move puts more weight on advisory services ahead of the upcoming earnings release. See our latest analysis for Adecco Group. The LHH launch comes as Adecco’s CHF23.20 share price sits slightly lower year to date, with a 4.3% 90 day share price return and an 11.5% 1 year total shareholder return, suggesting recent momentum has picked up after a weaker multi year...

ams-OSRAM’s ongoing turnaround has involved restructuring and moving away from low-margin LED activities toward automotive and industrial optical semiconductor applications, with management stressing operational improvements and debt reduction as priorities. An interesting angle is how investors and analysts are closely watching AI-driven demand for optical sensors as a potential earnings catalyst, while still highlighting considerable execution and leverage risks. Next, we’ll examine how...

As you might know, Roche Holding AG ( VTX:ROG ) recently reported its annual numbers. It was a pretty mixed result...

UBS Group (SWX:UBSG) has appointed Nicholas Hinnen as head of premium advisory specialists APAC Switzerland. The newly created role oversees a cross asset advisory team for ultra high and high net worth wealth management clients. The promotion reflects UBS's focus on its Swiss based affluent client segment and tailored advisory services. For you as an investor, this move highlights how UBS is leaning into its core wealth management franchise, where personalised advice and cross asset...

BD and Ypsomed Holding (SWX:YPSN) are expanding their collaboration around a new 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe, tailored for Ypsomed’s YpsoMate 5.5 large volume autoinjector platform. See our latest analysis for Ypsomed Holding. Despite the expanded BD partnership around large volume injectors, Ypsomed Holding’s 1 day share price return of 0.16% comes after a softer patch, with a 30 day share price return of 6.71% and a 1 year total shareholder return of 12.36%. This...